HERCEPTIN HYLECTA
PeakmAbBLASUBCUTANEOUSINJECTABLE
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
HERCEPTIN HYLECTA by Roche is her2 (or c-erbb2) proto-oncogene encodes a transmembrane receptor protein of 185 kda, which is structurally related to the epidermal growth factor receptor. Approved for more chemotherapy regimens for metastatic disease. First approved in 2019.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERCEPTIN HYLECTA is a subcutaneous injection combining trastuzumab (a HER2-targeted monoclonal antibody) with hyaluronidase to enable rapid subcutaneous delivery. It treats HER2-positive breast cancer by antagonizing HER2/neu receptor signaling, offering patients a faster, more convenient alternative to intravenous trastuzumab administration.
$0.514MPart D
PeakProduct is in peak commercial stage with modest Part D utilization; career roles focus on manufacturing and operational excellence rather than expansion.
Mechanism of Action
HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2.…
Indications (1)
Worked on HERCEPTIN HYLECTA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.